DesignMedix places great emphasis on tackling problems of drug resistant diseases, such as malaria, bacteria, and cancer. There is a huge market for creating new drugs as each disease needs multiple treatments. DesignMedix’s solution to the problem is creating novel drugs that overcome resistance that leverages safety and effectiveness of initial drugs, which in turn decreases time and risk of drug development.
Currently, the company has created a new, stable low-cost manufacture drug that kills drug-resistant malaria. In clinical tests, the drug has been potent in killing drug-resistant malaria in all patient samples. The company aims to acquire a potential exit strategy through prospective buyers from Generics companies serving the malaria market.
Through our news, radio interviews, video production, and research, OneMedPlace specializes in delivering information to investors covering nanocap, microcap and private emerging growth companies in the hottest areas of life sciences. OneMedPlace covers what we believe to be an undervalued sector, and has built a network of investors at all levels of financial and strategic development. OneMedPlace produces two investor conferences, OneMedForumSF in January and OneMedForumNY in June, bringing together our diverse network to meet the most promising companies in life sciences. Visit our website to learn more about attending.